Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
For sufferers with HR+, HER2- early breast most cancers, MammaPrint might predict distant recurrence-free interval prognosis and chemotherapy profit.Amongst sufferers with hormone receptor-positive...
The FDA has granted Quick Monitor designation to the most cancers vaccine GLSI-100 for sufferers with HLA-A*02-positive and HER2-positive breast most cancers.The U.S....
Lung most cancers analysis has acknowledged the function of EGFR mutations in driving the illness for about 20 years, with most sufferers presenting...
The FDA has authorized Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder most cancers with carcinoma in situ.The U.S. Meals and Drug Administration...
